FDA Brief

Warning letters Drugs

FDA warning letter to

www.portmeds.com

High riskIssued Jul 16, 2025Posted Jul 29, 2025Center for Drug Evaluation and Research (CDER)

FDA warned www.portmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants online without prescriptions.

What happened

FDA reviewed the website www.portmeds.com and found it offering unapproved and misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers, plus prescription drugs without a prescription. The letter says website claims show the products are drugs intended for human use, but no FDA-approved applications are in effect for the named products. No inspection was stated; FDA found the issues through its website review.

What FDA found

  1. The website offered opioids, benzodiazepines, and Schedule II stimulants that are new drugs without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  2. The website's drug labeling did not include adequate directions for safe use by a layperson, so FDA calls the drugs misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; section 301(a) [21 U.S.C. § 331(a)]
  3. The website offered prescription drugs, including Percocet, for sale without requiring a prescription.

    FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
  4. The website marketed specific opioid products such as tapentadol, hydrocodone, oxycodone, and tramadol under labels FDA has not approved.

    FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]

What FDA wants

FDA asks www.portmeds.com to stop offering unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days with the specific steps taken and supporting documents.

Who should pay attention

  • consumers who buy prescription drugs online
  • online pharmacy operators and affiliates
  • platforms and payment or shipping partners that serve drug websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk